Business Services
Cancer Prevention
Medical

Celcuity

$23.47
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.17 (0.73%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell Celcuity and other stocks, options, ETFs, and crypto commission-free!

About

Celcuity Inc. Common Stock, also called Celcuity, is cellular analysis company. Read More The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. Its proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded in January 2012 by Brian Sullivan and Lance Laing and is headquartered in Minneapolis, MN.

Employees
26
Headquarters
Minneapolis, Minnesota
Founded
2012
Market Cap
237.87M
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
14.72K
High Today
$23.50
Low Today
$22.98
Open Price
$23.50
Volume
5.05K
52 Week High
$31.00
52 Week Low
$18.28

Collections

Business Services
Cancer Prevention
Medical
Technology
Therapy
Health
2017 IPO
US

News

Yahoo FinanceMay 13

Celcuity, Inc. Upgraded to Buy: What Does It Mean for the Stock?

Celcuity, Inc. (CELC) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. Celcuity, Inc. (CELC) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change. A company's changing earnings picture is at the core of the Zacks rating. The syste...

12
Seeking AlphaMay 7

Celcuity beats by $0.04

Celcuity (NASDAQ:CELC): Q1 Non-GAAP EPS of -$0.16 beats by $0.04; GAAP EPS of -$0.18 beats by $0.03. Press Release...

6
Yahoo FinanceMay 7

Celcuity Reports First Quarter 2019 Financial Results

MINNEAPOLIS--(BUSINESS WIRE)-- Celcuity Inc. (CELC), a functional cellular analysis company that is discovering new cancer subtypes and commercializing diagnostic tests designed to significantly improve clinical outcomes of cancer patients treated with targeted therapies, announced financial results for the first quarter ended March 31, 2019. Unless otherwise stated, all comparisons are for the first quarter ended March 31, 2019, compared to the first quarter ended March 31, 2018. Celcuity reported a net...

2

Earnings

-$0.25
-$0.21
-$0.18
-$0.14
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
—
Actual
Expected Aug 8, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.